BACARDI
15.6.2022 13:02:07 CEST | Business Wire | Press release
Bacardi, the largest privately held spirits company in the world, has expanded its pioneering TAILS® COCKTAILS PROFESSIONAL range with new cocktails and a new look, available now for the hospitality industry across Western Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005150/en/
The premium batched cocktail brand offers the on-trade a hassle-free solution for serving quality cocktails easily, quickly and consistently at scale. Serving a TAILS cocktail takes as little as 15 seconds, and no specialist training is required.
The expanded range of classic and contemporary cocktails, all crafted using the Bacardi portfolio of premium brands has two new additions; the Whisky Sour , made with DEWAR’S® Blended Scotch whisky; and the Rum Punch , made with BACARDĺ® rum.
“Thousands of outlets across Europe are already enjoying a new revenue stream by serving TAILS COCKTAILS PROFESSIONAL, and this year we’re planning to more than double that number – the momentum is huge,” says Evert-Jan Bos, General Manager, TAILS COCKTAILS.
He adds: “With the new flavors, we’re catering for even more tastes and occasions – from summer terraces to cosy winter bars – offering an exciting opportunity for the hospitality industry to tap into the growing demand for cocktails.”
The expanded range also includes the Passion Fruit Martini Cocktail and Espresso Martini Cocktail , both made with 42BELOW® vodka; the Gin Garden Cocktail made with BOMBAY® Dry gin and ST-GERMAIN® elderflower liqueur; and the Classic Mojito and Berry Mojito , both made with BACARDĺ rum.
As well as the new-look 1L bottles, there are also three TAILS COCKTAILS PROFESSIONAL 20L kegs - the Passion Fruit Spritz made with 42BELOW® vodka, and the Classic Mojito and Caribbean Punch , both made with BACARDÍ rum – rolling out this summer, allowing outlets to serve cocktails on draught for even quicker, easier service.
With a full live music and events line-up back in Europe this year, Bacardi will also bring high quality cocktails to festivals at scale, with TAILS COCKTAILS PROFESSIONAL at more than 20 of the biggest festivals across the UK, Spain, Belgium and the Netherlands.
The range sits alongside the company’s recent launch of TAILS COCKTAILS , which takes TAILS into the off-trade for the first time, pioneering a new ‘ready-to-shake’ category within cocktails-at-home.
For more information, visit www.tailscocktails.com/professional .
Always drink responsibly
About the TAILS® COCKTAILS PROFESSIONAL range
TAILS COCKTAILS crafts expertly batched cocktails to ensure consistent quality and speed of service throughout the hospitality and events industry. Established in 2010, TAILS COCKTAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS cocktail begins with the highest quality, premium spirits – BACARDI® rum, 42BELOW® vodka, BOMBAY SAPPHIRE® gin, DEWAR’S® Blended Scotch whisky and ST-GERMAIN® elderflower liqueur – blended with top quality ingredients. The range is available in both 1L bottles and 20L kegs with draught pillars. The TAILS COCKTAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Visit www.tailscocktails.com/professional .
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY® Dry gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom